Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect and Bioavailability Study of Nifurtimox in Chagas' Disease
NCT03334838Phase 1Completed
- Sponsor
- Bayer
- Start
- Jun 2019
- Primary completion
- Nov 2019
- Modality
- Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of nifurtimox in Chagas disease (2 arms), sponsored by Bayer. Primary endpoints: Area Under the Curve (AUC0-tlast) and Maximum Plasma Concentration. Started Jun 2019; status: completed.
02
Drugs
nifurtimox
03
Conditions
Chagas disease
Beyond the preview
Go deeper on NCT03334838.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334838.